Pacira BioSciences, Inc. (NasdaqGS: PCRX)
Health Care · Pharmaceuticals · US
$36.39
+44.40% today · +55.4% 1Y
Pacira BioSciences, Inc. (NasdaqGS: PCRX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.45B and employs 827 people.
Over the last twelve months the share price has gained 55.4%, trading between 18.80 and 27.66.
Tweenvest scores Pacira BioSciences, Inc. across four factors: quality 74/100, value 62/100, growth 55/100. Its strongest factor is quality.
PCRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.45B
- Revenue (TTM)
- $746.16M
- P/E
- 103.45
- EPS
- 0.35
- Dividend yield
- —
- Beta (5Y)
- 0.25
- 52-week high
- $27.66
- 52-week low
- $18.80
- Avg volume (3M)
- —
- Shares outstanding
- 39.86M
- Employees
- 827
- Next earnings
- —
About Pacira BioSciences, Inc.
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
- ISIN
- US6951271005
- Founded
- 2006
- Listed since
- Feb 3, 2011
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Maze Therapeutics, Inc.NasdaqGM: MAZE | $1.47B | $25.88 | -2.08% |
| Yifan Pharmaceutical Co., Ltd.SZSE: 002019 | $1.46B | CN¥9.42 | +0.64% |
| Tianjin Chase Sun Pharmaceutical Co.,LtdSZSE: 300026 | $1.46B | CN¥3.25 | +2.20% |
| Xiamen Kingdomway Group CompanySZSE: 002626 | $1.45B | CN¥16.13 | -0.37% |
| Ningbo Menovo Pharmaceutical Co., Ltd.SHSE: 603538 | $1.45B | CN¥28.59 | +6.84% |
| Zhejiang Jingxin Pharmaceutical Co., Ltd.SZSE: 002020 | $1.45B | CN¥11.83 | +4.32% |
| Mayinglong Pharmaceutical Group Co., Ltd.SHSE: 600993 | $1.45B | CN¥22.52 | +1.67% |
| Guangdong Taienkang Pharmaceutical Co., Ltd.SZSE: 301263 | $1.45B | CN¥19.09 | -3.63% |
Figures last refreshed Oct 4, 2026.